Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna (MRNA) remains at the forefront of mRNA technology innovation, developing transformative therapies for infectious diseases, oncology, and rare conditions. This dedicated news hub provides investors and healthcare professionals with essential updates directly from the company and verified sources.
Access official press releases covering clinical trial results, regulatory milestones, and strategic partnerships, alongside analysis of quarterly earnings and pipeline developments. Our curated collection ensures you stay informed about Moderna's progress in advancing mRNA-based medicines without promotional bias.
Key updates include developments in respiratory vaccines, cancer immunotherapy candidates, and rare disease treatments. Bookmark this page for real-time access to Moderna's verified announcements and objective reporting on one of biotechnology's most innovative platforms.
Moderna (NASDAQ:MRNA) announced its upcoming participation in two major investor conferences: the 2022 Jefferies Healthcare Conference on June 8 at 3:00 p.m. ET and the 43rd Annual Goldman Sachs Global Healthcare Conference on June 14 at 12:20 p.m. ET. Live webcasts will be available on the Moderna investor website, with replays archived for at least 30 days. Moderna has evolved from a research-stage company to a leader in mRNA therapeutics, having developed vaccines and therapeutics for various diseases, including a highly effective COVID-19 vaccine.
Moderna has announced that it will assume the role of marketing authorization holder for its COVID-19 vaccine Spikevax™ in Japan starting August 1, 2022. This transition includes taking over all related activities, such as import, regulatory compliance, development, quality assurance, and commercialization. In a collaborative effort, Takeda will continue to provide distribution support during a transitional phase of the national vaccination campaign. Both companies aim to ensure smooth operational implementation during this handover.
Moderna announces it will take over as the marketing authorization holder for its COVID-19 vaccine, SpikevaxTM, in Japan starting August 1, 2022. This transition from Takeda includes responsibilities for import, local regulations, development, quality assurance, and commercialization. Takeda will continue to provide distribution support during a transitional period. This move aims to strengthen Moderna's commercial organization in Japan as it continues to combat the COVID-19 pandemic.
Moderna (Nasdaq: MRNA) will participate in a fireside chat at the UBS 2022 Global Healthcare Conference on May 24 at 9:15 a.m. ET. A live webcast will be available on the company's investor website, with a replay accessible for 30 days post-event. Moderna, known for its mRNA technology, has evolved from a research company to a leader in developing vaccines and therapeutics across various diseases, including COVID-19, reinforcing its position in the biopharmaceutical sector.
IAVI and Moderna announced a Phase I clinical trial in Rwanda and South Africa to assess the safety and immunogenicity of an mRNA HIV vaccine antigen (mRNA-1644). This trial, known as IAVI G003, follows promising results from a prior study that indicated 97% of participants developed targeted immune responses. The trial aims to enroll 18 healthy, HIV-negative adults who will receive two doses of the vaccine. This initiative is supported by the U.S. government and the Bill & Melinda Gates Foundation, aiming to strengthen scientific capacity in regions heavily impacted by HIV.
Moderna detailed advancements in its mRNA platform during its 5th Annual Science and Technology Day, focusing on innovative delivery methods, including pulmonary applications. The company is collaborating with Vertex to develop treatments for cystic fibrosis via inhalation. Evidence supports the safety of its COVID-19 vaccines for pregnant and breastfeeding women. The firm emphasizes the importance of mRNA stability for product shelf-life, achieving improved manufacturing processes. Moderna's ongoing research aims to optimize clinical applications of mRNA across various diseases.
Moderna, Inc. (NASDAQ:MRNA) announced the immediate departure of its Chief Financial Officer, Jorge Gomez, amidst an ongoing internal investigation at his previous employer, Dentsply Sirona Inc. In light of this, David Meline, the recently retired CFO, will resume his role as CFO while the company searches for a new candidate. Moderna emphasizes that these changes come with risks and uncertainties, and encourages stakeholders to refer to its latest filings for detailed risk factors.
Moderna (NASDAQ:MRNA) will host its in-person Science and Technology Day for analysts and investors on May 17, 2022, at 9:00 a.m. ET in Boston, MA. Key presentations will be made by President Stephen Hoge, Chief Scientific Officer Melissa Moore, and other scientists highlighting advances in mRNA technology.
A live webcast will be available on Moderna's investor website, with a replay accessible for one year. Moderna has transformed significantly over the past decade, developing a diverse portfolio of vaccines and therapeutics, particularly noted for its effective COVID-19 vaccine.
Moderna reported strong Q1 2022 results, achieving revenues of $6.1 billion and a net income of $3.7 billion, resulting in a diluted EPS of $8.58. The company reaffirmed its 2022 advance purchase agreements totaling $21 billion and outlined plans for four Phase 3 programs in the second quarter, including COVID booster and flu vaccines. Moderna's pipeline now has 46 programs with 29 in clinical trials, showing robust progress in both preventive and therapeutic mRNA applications.
Moderna (NASDAQ: MRNA) has submitted a variation for conditional marketing authorization to the European Medicines Agency (EMA) for its COVID-19 vaccine, Spikevax, targeting children six months to under six years. This follows the EMA's positive recommendation for use in children aged six years and older. Positive interim results indicated strong antibody responses and a favorable safety profile from the Phase 2/3 KidCOVE study. Efficacy estimates for the younger age group showed 51% effectiveness against Omicron. The company also continues to explore booster doses for pediatric populations.
